公司近况5 月23 日,2025 ASCO会议部分摘要公布。信达生物读出多个重磅数据,包括七项口头报告,其中IBI363(PD-1/IL-2)读出的黑色素瘤、肠癌、非小细胞肺癌概念验证(PoC)数据引人注目。评论IBI363 肠癌后线数据较大超我们预期。截至2024 年12 月6 日1:患者基线单药组和联合组分别有63.2%和53.4%此前已经接受过3 线及以上的治疗。在疗效可评估患者中(单药组 ...
Source Link公司近况5 月23 日,2025 ASCO会议部分摘要公布。信达生物读出多个重磅数据,包括七项口头报告,其中IBI363(PD-1/IL-2)读出的黑色素瘤、肠癌、非小细胞肺癌概念验证(PoC)数据引人注目。评论IBI363 肠癌后线数据较大超我们预期。截至2024 年12 月6 日1:患者基线单药组和联合组分别有63.2%和53.4%此前已经接受过3 线及以上的治疗。在疗效可评估患者中(单药组 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.